The US Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for people living with spinal muscular atrophy (SMA).
Lexaria Bioscience (LEXX) has made a strategic business decision to further investigate the commercial opportunities and applications for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback